| Lisocabtagene Maraleucel studied in …STUDIED_INderived23 of 23show fewer |
|---|
| → studied in | NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · 23 trials list this drug (14 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · 23 trials list this drug (14 active) | — | — | Diffuse Large B-Cell Lymphoma,Indolent B-Cell Non-Hodgkin Lymphoma,Primary Mediastinal Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07194980Phase 2 · recruiting Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 23 trials list this drug (14 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07777120active not recruiting Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma · 23 trials list this drug (14 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05075603Phase 1 · completed Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy · 23 trials list this drug (14 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07188558Phase 3 · recruiting A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy · 23 trials list this drug (14 active) | — | — | B-Cell Malignant Neoplasm,Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07711483Phase 2 · not yet recruiting GLORY: Glofit-GemOx With Liso-Cel For Lymphoma · 23 trials list this drug (14 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03331198Phase 1/Phase 2 · active not recruiting Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) · 23 trials list this drug (14 active) | — | — | Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672173Phase 2 · active not recruiting Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation · 23 trials list this drug (14 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05873712Phase 2 · recruiting Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome · 23 trials list this drug (14 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma,Transformed Non-Hodgkin Lymphoma,Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633615Phase 2 · recruiting Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · 23 trials list this drug (14 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583149Phase 2 · active not recruiting Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas · 23 trials list this drug (14 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357754recruiting Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy · 23 trials list this drug (14 active) | — | — | Multiple Myeloma,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04855253Phase 1/Phase 2 · suspended Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL · 23 trials list this drug (14 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04245839Phase 2 · active not recruiting A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) · 23 trials list this drug (14 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03744676Phase 2 · completed A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) · 23 trials list this drug (14 active) | — | — | Neoplasm,B-Cell Malignant Neoplasm,Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788639recruiting A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting · 23 trials list this drug (14 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788652recruiting A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting · 23 trials list this drug (14 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06794268recruiting A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting · 23 trials list this drug (14 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03484702Phase 2 · completed Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma · 23 trials list this drug (14 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03743246Phase 1/Phase 2 · terminated A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) · 23 trials list this drug (14 active) | — | — | Acute Lymphoblastic Leukemia,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03310619Phase 1/Phase 2 · completed A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies · 23 trials list this drug (14 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03483103Phase 2 · completed Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) · 23 trials list this drug (14 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |